Poolbeg Pharma yesterday announced a deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery programme aimed at identifying potential drug development candidates for the treatment of influenza. The move represents Poolbeg's second foray into AI-based
24 Mar 2022
Further expansion of AI-based R&D
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Further expansion of AI-based R&D
Poolbeg Pharma PLC (POLB:LON) | 10.6 0 2.9% | Mkt Cap: 53.2m
- Published:
24 Mar 2022 -
Author:
Robin Davison -
Pages:
3
Poolbeg Pharma yesterday announced a deal with the Israeli artificial intelligence (AI)-based biotech CytoReason to conduct a drug discovery programme aimed at identifying potential drug development candidates for the treatment of influenza. The move represents Poolbeg's second foray into AI-based